Cardinal Health, Inc. (CAH) fair value analysis

S&P 500 · Updated 2026-09-07

Cardinal Health, Inc. is a healthcare services company that distributes pharmaceutical products, medical supplies, and equipment to hospitals, pharmacies, and healthcare providers across the United States and internationally. The company also operates a global manufacturing segment that produces generic drugs and other pharmaceutical products for healthcare systems worldwide.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, CAH is trading at a 10–25% premium to estimated fair value.

CAH currently ranks #97 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $247.18
Sector: Healthcare
12-month range: $190.22–$239.35

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: F
Leverage: Low
Margin trend: Stable
Revenue growth: Modest
RSI zone: Neutral
52-week position: The top quarter of its range
DCF cross-check: Overvalued

What our data shows for CAH

Our model validated 17 trailing price-to-earnings windows for CAH, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $190.22–$239.35.
The 14-day relative strength index sits at a neutral 60.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for CAH
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent CAH news

TickrTrends' derived news-sentiment signal for CAH is currently leaning positive, computed from recent coverage.

Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore” (insidermonkey.com, 2026-09-03)
TickrTrends take: Cardinal Health trades at a valuation that TickrTrends currently assesses as overvalued within the Healthcare sector, which creates a tension between positive sentiment from prominent commentators and fundamental valuation metrics. Investors focused on valuation discipline would need to monitor whether the company's operational performance or market conditions shift sufficiently to justify the current price level relative to sector peers. The gap between market enthusiasm and valuation assessment suggests watching for either a correction in the stock price or improvements in earnings that could reconcile the overvaluation signal.

What people are saying

Follow the CAH conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for CAH in the Healthcare sector show that momentum has moved from A to none this week, while the company's sector discount rank has declined from #92 to #97. The current valuation verdict remains Overvalued.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is CAH stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), CAH is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is CAH's TickrTrends verdict?

CAH's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does CAH compare to other Healthcare stocks?

CAH ranks #97 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is CAH overbought or oversold?

CAH's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

CAH vs BMY · CAH vs CNC · CAH vs CRL · CAH vs CVS · CAH vs ILMN